Nurix Therapeutics (NASDAQ:NRIX) Posts Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) announced its earnings results on Monday. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33, Zacks reports. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%. The business had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $22.13 on Wednesday. The firm has a market cap of $2.30 billion, a P/E ratio of -6.41 and a beta of 1.82. Nurix Therapeutics has a fifty-two week low of $9.14 and a fifty-two week high of $28.23. The firm has a 50-day simple moving average of $25.17 and a two-hundred day simple moving average of $21.00.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Mizuho boosted their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Robert W. Baird upped their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday. Truist Financial reduced their price objective on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday. Wall Street Zen raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Finally, BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research note on Friday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.64.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the registrational Phase 3 DAYBreak CLL-306 trial, dosing the first patient in a study comparing bexobrutideg with pirtobrutinib (Jaypirca) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Positive Phase 1/2 results could support a potential accelerated approval in later-line disease. Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Analysts remain bullish: Robert W. Baird raised its price target to $36 and maintained an outperform rating, while Needham reaffirmed a buy rating with a $34 target. Truist kept a buy rating despite trimming its target to $33. These targets imply substantial upside from recent trading levels.
• Positive Sentiment: Nurix’s third-quarter results significantly exceeded expectations, with earnings of $4.73 per share versus consensus estimates for a loss of approximately $0.56–$0.60 and revenue of $673.1 million versus an estimate of $24.4 million. The results provide financial support for continued clinical development. Nurix Q3 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: RBC Capital Markets argues that Nurix’s enterprise value remains underappreciated, supporting the valuation case, although the thesis depends heavily on successful clinical execution and future commercialization.
• Negative Sentiment: Nurix faces heightened risks from its reliance on Roche, including cost burdens, reduced control over development and commercialization decisions, and uncertain returns from bexobrutideg. These concerns may be limiting the stock’s reaction to strong earnings and favorable clinical updates. Nurix’s Reliance on Roche and Bexobrutideg Risks

Insider Activity

In other news, insider Gwenn Hansen sold 4,356 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the transaction, the insider owned 117,227 shares in the company, valued at approximately $2,930,675. This represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hans van Houte sold 4,761 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,372 shares of company stock valued at $518,463 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.